The amount of daily dosage of empagliflozin in the trial.

No definition available.

Name:	iva_DailyDoseOfEmpagliflozinInTrial
Namespace Prefix:	iva_
Data Type:	dtr-types:massItemType
Balance Type:	na
Period Type:	duration

- Definition

Daily dose of lanifibranor in trial

+ References

No definition available.

+ Details

Name:	iva_DailyDoseOfLanifibranorInTrial
Namespace Prefix:	iva_
Data Type:	dtr-types:massItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of increase of Hemoglobin in patients with MASH and T2D.

+ References

No definition available.

+ Details

Name:	iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of reduction in Hemoglobin among patients with MASH and T2D.

+ References

No definition available.

+ Details

Name:	iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy

+ References

No definition available.

+ Details

Name:	iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF.

+ References

No definition available.

+ Details

Name:	iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of significant relative reduction in VAT / SAT ratio in patients.

+ References

No definition available.

+ Details

Name:	iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Duration of clinical trial

+ References

No definition available.

+ Details

Name:	iva_DurationOfClinicalTrial
Namespace Prefix:	iva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.

+ References

No definition available.

+ Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems
Namespace Prefix:	iva_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of subjects randomized for main cohort.

+ References

No definition available.

+ Details

Name:	iva_NumberOfPatientsRandomizedClinicalTrialMainCohort
Namespace Prefix:	iva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of liver triglyceride reduction achieved in a higher proportion of patients.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfLiverTriglycerideReductionAchievedInHigherProportionOfPatients
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of patients in combination therapy.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfPatientsOnCombinationTherapy
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the percentage of patients on lanifibranor alone.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfPatientsOnLanifibranorAlone
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the percentage of patients saw their HbA1c levels below specific percentage mentioned.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfPatientsSawTheirHemoglobinLevelsBelowSpecifiedPercentageMentioned
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of patients treated in trial showing significant reduction in hepatic fat.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfPatientsTreatedInTrialShowingSignificantReductionInHepaticFat
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of reduction in placebo group.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfReductionOfPlaceboGroup
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the specific percentage of Hemoglobin levels presented.

+ References

No definition available.

+ Details

Name:	iva_SpecificPercentageOfHemoglobinLevel
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Treatment period under study

+ References

No definition available.

+ Details

Name:	iva_TreatmentPeriodUnderStudy
Namespace Prefix:	iva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=iva_PatientsTreatedWithLanifibranorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=iva_PatientsTreatedWithLanifibranorInCombinationWithEmpagliflozinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=iva_PatientsTreatedWithPlaceboMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Company information - Company to present the results of LEGEND Phase (Details)	Nov. 18, 2024	Mar. 18, 2024 item g	Jun. 13, 2023 g
Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease
Collaborative Arrangements
Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy			44.00%
Duration of clinical trial			168 days
Percentage of liver triglyceride reduction achieved in a higher proportion of patients			30.00%
Daily dose of lanifibranor in trial		0.80	800,000
Percentage of patients hemoglobin levels	50.00%
Specific percentage of hemoglobin level	6.50%
Percentage of patients On lanifibranor alone	58.00%
Percentage of reduction of placebo group	0.00%
LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Collaborative Arrangements
Number of patients in main cohort \| item		63
Daily dose of lanifibranor in trial		0.80
Daily dose of empagliflozin in trial		0.01
Treatment period under study		168 days
Minimum \| Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease
Collaborative Arrangements
Percentage reduction in results on treatments	1.00%
Minimum \| LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Collaborative Arrangements
Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy		30.00%
Patients treated with lanifibranor \| LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Collaborative Arrangements
Percentage reduction in results on treatments		1.14%
Reduction in hepatic steatosis (in percent)		(47.00%)
Percentage of patients showing significant reduction in hepatic fat		83.00%
Significant relative reduction in VAT/SAT ratio (in percent)		(5.00%)
Patients treated with lanifibranor in combination with empagliflozin \| Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease
Collaborative Arrangements
Percentage of patients On combination therapy	80.00%
Patients treated with lanifibranor in combination with empagliflozin \| LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Collaborative Arrangements
Percentage reduction in results on treatments		1.59%
Reduction in hepatic steatosis (in percent)		(38.00%)
Percentage of patients showing significant reduction in hepatic fat		67.00%
Significant relative reduction in VAT/SAT ratio (in percent)		(17.00%)
Patients treated with placebo \| LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Collaborative Arrangements
Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy		0.00%
Percentage of increase observed in the placebo arm		0.26%
Reduction in hepatic steatosis (in percent)		0.00%
Significant relative reduction in VAT/SAT ratio (in percent)		11.00%